Vertex Pharmaceuticals stock is trading -13.81% below its average target price of $481.8 after dropping -1.4% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $330.0 to $624.0 per share.
The stock has a very low short interest at 1.8%, and a short ratio of 2.83. The company's insiders own 0.14% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 98.3% of Vertex Pharmaceuticals's shares being owned by this investor type.
Institutions Invested in Vertex Pharmaceuticals
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Capital World Investors | 11% | 28,732,143 | $11,931,166,181 |
| 2025-06-30 | Vanguard Group Inc | 9% | 23,973,777 | $9,955,230,885 |
| 2025-06-30 | Blackrock Inc. | 9% | 21,871,945 | $9,082,434,627 |
| 2025-06-30 | Capital Research Global Investors | 6% | 16,108,291 | $6,689,048,457 |
| 2025-06-30 | State Street Corporation | 5% | 11,775,227 | $4,889,721,945 |
| 2025-06-30 | FMR, LLC | 2% | 6,406,372 | $2,660,278,036 |
| 2025-06-30 | Jennison Associates LLC | 2% | 6,151,505 | $2,554,443,238 |
| 2025-06-30 | Geode Capital Management, LLC | 2% | 5,928,747 | $2,461,941,864 |
| 2025-06-30 | JPMORGAN CHASE & CO | 2% | 5,869,361 | $2,437,281,530 |
| 2025-06-30 | Wellington Management Group, LLP | 2% | 4,813,386 | $1,998,782,626 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Vertex Pharmaceuticals.
